Evidence map›Paper›PMID 33977438›Full record

ArticleAdvances in experimental medicine and biology2021

Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.

Sevil Köse, Fatima Aerts-Kaya, Duygu Uçkan Çetinkaya, Petek Korkusuz

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
9.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. A kaleidoscopic view of extracellular vesicles in lysosomal storage disorders.Extracellular vesicles and circulating nucleic acids · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sevil KöseDepartment of Medical Biology, Faculty of Medicine, Atilim University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-2188-9534
Fatima Aerts-KayaDepartment of Stem Cell Sciences, Hacettepe University Graduate School of Health Sciences, Ankara, Turkey.ORCID https://orcid.org/0000-0002-9583-8572
Duygu Uçkan ÇetinkayaHacettepe University Faculty of Medicine, Department of Pediatrics, Division of Hematology, Hacettepe University Center for Stem Cell Research and Development (PEDI-STEM), Ankara, Turkey.ORCID https://orcid.org/0000-0003-3593-6493
Petek KorkusuzDepartment of Histology and Embryology, Hacettepe University Faculty of Medicine, Ankara, Turkey. petek@hacettepe.edu.tr.ORCID https://orcid.org/0000-0002-7553-3915
Hacettepe University · TRAtilim University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysosomal storage disorders (LSDs) are rare inborn errors of metabolism caused by defects in lysosomal function. These diseases are characterized by accumulation of completely or partially degraded substrates in the lysosomes leading to cellular dysfunction of the affected cells. Currently, enzyme replacement therapies (ERTs), treatments directed at substrate reduction (SRT), and hematopoietic stem cell (HSC) transplantation are the only treatment options for LSDs, and the effects of these treatments depend strongly on the type of LSD and the time of initiation of treatment. However, some of the LSDs still lack a durable and curative treatment. Therefore, a variety of novel treatments for LSD patients has been developed in the past few years. However, despite significant progress, the efficacy of some of these treatments remains limited because these therapies are often initiated after irreversible organ damage has occurred.Here, we provide an overview of the known effects of LSDs on stem cell function, as well as a synopsis of available stem cell-based cell and gene therapies that have been/are being developed for the treatment of LSDs. We discuss the advantages and disadvantages of use of hematopoietic stem cell (HSC), mesenchymal stem cell (MSC), and induced pluripotent stem cell (iPSC)-related (gene) therapies. An overview of current research data indicates that when stem cell and/or gene therapy applications are used in combination with existing therapies such as ERT, SRT, and chaperone therapies, promising results can be achieved, showing that these treatments may result in alleviation of existing symptoms and/or prevention of progression of the disease. All together, these studies offer some insight in LSD stem cell biology and provide a hopeful perspective for the use of stem cells. Further development and improvement of these stem cell (gene) combination therapies may greatly improve the current treatment options and outcomes of patients with a LSD.

Indexed as

Lysosomal Storage DiseasesEnzyme Replacement TherapyGenetic TherapyHematopoietic Stem CellsHumansLysosomesGene therapyHematopoietic stem cellInduced pluripotent stem cellLysosomal storage diseaseLysosomal storage disorderMesenchymal stem cellNeural stem cellStem cell

Identifiers

PMID33977438
OpenAlexW3163316651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.